Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Université Pierre et Marie Curie. Paris VI and Hôpital Pitié-Salpêtrière. Paris, France.
University of California San Diego. San Diego, California, USA.
Quest Clinical Research. San Francisco, California, USA.
San Raffaele University. Vita-Salute. Milan, Italy.
Centro de Referência e Treinamento DST/AIDS. São Paulo, Brasil.
University of Paris. Saint-Louis Hospital. Department of Infectious Diseases. France.
Universidade Federal do Rio de Janeiro. Projeto Praça Onze. Rio de Janeiro, RJ, Brasil.
Tibotec BVBA. Mechelen, Belgium.
Tibotec, Inc. Yardley, Pennsylvania, USA.
Tibotec BVBA. Mechelen, Belgium.
Tibotec BVBA. Mechelen, Belgium.
Tibotec BVBA. Mechelen, Belgium.

Abstract

To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in treatment-experienced adults infected with HIV-1 strains resistant to a nonnucleoside reverse transcriptase inhibitor and other antiretrovirals.

Keywords

Antiretroviral agents
DUET
Etravirine
HIV
Nonnucleoside reverse transcriptase inhibitor
TMC125

Publisher

Wolters Kluwer Health | Lippincott Williams & Wilkins

Citation

KATLAMA, C. et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS, v. 23, n. 17, p. 2289-2300, 2009.

DOI

10.1097/QAD.0b013e3283316a5e

ISSN

1473-5571

Notes

Presente no DUET-1: Beatriz Grinsztejn (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil).

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30346

Type

Copyright

Restricted access

Embargo date

2025-08-30

Collections

Share

Statistics

Metadata

Author

Affilliation